首页> 外国专利> Compsn. for prophylaxis of the haemolytic disease of the new-born

Compsn. for prophylaxis of the haemolytic disease of the new-born

机译:Compsn。预防新生儿溶血病

摘要

Compsn. comprises a mixt. of at least 2 human monoclonal antibodies (MAbs), one of sub-class IgG1 and one of sub-class IgG2, which each recognise Rhesus D, but not C, c, E or e antigens and whose combination permits the detection of the majority of partial D antigens. The MAb of sub-class IgG1 is produced by the heterohybridoma (HH) cell line DSM ACC 2039, and the MAb of sub-class IgG3 is produced by the HH cell line DSM ACC 2040. Also claimed are the human/mouse HH cell lines as filed with the 'Deutsche Sammlung von Mikroorganism and Zellkulfuren, DSM ACC 2039 and 2040. The mixt. of the two Abs pref. comprises 30-70% of IgG3 and the cell lines are not EBV transformed.
机译:Compsn。包括混音。的至少2种人类单克隆抗体(MAb),一种为IgG1子类别,另一种为IgG2子类别,它们各自识别恒河猴D,但不识别C,c,E或e抗原,并且其结合可以检测到大多数部分D抗原。 IgG1亚类的MAb由杂种瘤(HH)细胞系DSM ACC 2039产生,IgG3亚类的MAb由HH细胞系DSM ACC 2040产生。还要求保护人类/小鼠HH细胞系。如“ Deutsche Sammlung von Mikroorganism和Zellkulfuren”,DSM ACC 2039和2040所提交的。两个Abs pref。包含30-70%的IgG3,且细胞系未进行EBV转化。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号